Product Program year 2025 Source: CMS Open Payments

Herceptin

Biological BioOncology

NDC 50242-132-01

Open in the dashboard

General payments

$3,499,184

701 payments

Research payments

$33,574,344

2,896 payments

Through program year 2025, $3,499,184 in general payments and $33,574,344 in research payments were reported against Herceptin (BioOncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $70,613 78
2025 Research $5,115,746 279
2024 General $6,629 105
2024 Research $3,806,979 331
2023 General $8,927 88
2023 Research $4,755,875 417
2022 General $391,901 186
2022 Research $9,702,135 801
2021 General $2,639,571 115
2021 Research $8,881,480 997
2020 General $171,559 32
2020 Research $683,282 58
2019 General $209,984 97
2019 Research $628,847 13

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech, Inc. $2,601,034 56 payments
  2. Genentech USA, Inc. $874,036 617 payments
  3. F. Hoffmann-La Roche AG $20,305 25 payments
  4. Chugai Pharmaceutical Co., Ltd. $3,808 3 payments
Top recipients General payments · program year 2025
  1. Joyce O'Shaughnessy Medical Oncology · Dallas, TX $7,918 11% · 6 payments
  2. Yuan Yuan Medical Oncology · Pasadena, CA $5,709 8% · 3 payments
  3. Vijayakrishna Gadi Medical Oncology · Seattle, WA $4,069 6% · 2 payments
  4. Joseph Sparano Medical Oncology · Bronx, NY $4,069 6% · 2 payments
  5. Abirami Sivapiragasam Hematology & Oncology · Syracuse, NY $3,957 6% · 6 payments

The top 5 of 32 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Medical Oncology Internal Medicine $46,858 69% · 16 practitioners
  2. Hematology & Oncology Internal Medicine $18,865 28% · 10 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $900 1% · 1 practitioner
  4. Physician Assistant $750 1% · 1 practitioner
  5. Nurse Practitioner, Gerontology Nurse Practitioner $750 1% · 1 practitioner

The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $16,545 23% · 6 recipients
  2. Massachusetts $9,367 13% · 4 recipients
  3. Texas $7,969 11% · 2 recipients
  4. Illinois $7,526 11% · 2 recipients
  5. California $6,367 9% · 6 recipients

The top 5 of 14 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

698

Prescriptions dispensed, refills included

Drug cost

$3,376,946

Paid at the pharmacy, in all

Medicare Part D drugs matched to Herceptin, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Herceptin Trastuzumab Same name 31 673 $3,264,667
Herceptin Hylecta Trastuzumab-Hyaluronidase-Oysk Similar name 2 25 $112,279

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 33 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Rahul Naik Hematology-Oncology CA 62 $313,590 None on record
Antoine Chahine Medical Oncology OH 59 $229,767 None on record
Maria Scouros Hematology-Oncology TX 49 $216,404 None on record
Swetha Yadav Hematology-Oncology TX 45 $224,901 None on record
Arjun Iyengar Hematology-Oncology NY 31 $125,541 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 33 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Herceptin
Billing code Providers Services Paid by Medicare
Injection, trastuzumab, 10 mg J9355 10 25,017 $1,552,921

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

701 general · 2,896 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record